Early Treatment with Anti-VLA-4 mAb Can Prevent the Infiltration and/or Development of Pathogenic CD11b+CD4+ T Cells in the CNS during Progressive EAE

The Benefits and Detriments of Macrophages/Microglia in Models of Multiple Sclerosis

(2013) Khalil S. Rawji et al.   Clinical & Developmental Immunology

Epithelial V-Like Antigen Mediates Efficacy of Anti-Alpha4 Integrin Treatment in a Mouse Model of Multiple Sclerosis

(2013) Erik Wright et al.   PLoS One

The discovery of natalizumab, a potent therapeutic for multiple sclerosis

(2012) Lawrence Steinman   JOURNAL OF CELL BIOLOGY

Myelin Basic Protein-Specific TCR/HLA-DRB5*01:01 Transgenic Mice Support the Etiologic Role of DRB5*01:01 in Multiple Sclerosis

(2012) J. A. Quandt et al.   JOURNAL OF IMMUNOLOGY

Targeted blockade in lethal West Nile virus encephalitis indicates a crucial role for very late antigen (VLA)-4-dependent recruitment of nitric oxide-producing macrophages

(2012) Daniel R Getts et al.   Journal of Neuroinflammation

Natalizumab strongly suppresses cortical pathology in relapsing–remitting multiple sclerosis

(2012) F Rinaldi et al.   Multiple Sclerosis Journal

Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE

(2011) Veit Rothhammer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Anaphylaxis and Mortality Induced by Treatment of Mice with Anti-VLA-4 Antibody and Pertussis Toxin

(2011) N. Ji et al.   JOURNAL OF IMMUNOLOGY

Role for MyD88, TLR2 and TLR9 but Not TLR1, TLR4 or TLR6 in Experimental Autoimmune Encephalomyelitis

(2011) S. Miranda-Hernandez et al.   JOURNAL OF IMMUNOLOGY

RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation

(2011) Laura Codarri et al.   NATURE IMMUNOLOGY

The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF

(2011) Mohamed El-Behi et al.   NATURE IMMUNOLOGY

Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool

(2011) Bahareh Ajami et al.   NATURE NEUROSCIENCE

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies

(2010) Dirk Fitzner et al.   Current Neuropharmacology

Toll-like Receptor 2 Signaling in CD4+ T Lymphocytes Promotes T Helper 17 Responses and Regulates the Pathogenesis of Autoimmune Disease

(2010) Joseph M. Reynolds et al.   IMMUNITY

Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report

(2010) F. Rinaldi et al.   NEUROLOGICAL SCIENCES

Engagement of Toll‐Like Receptor 2 on CD4+T Cells Facilitates Local Immune Responses in Patients with Tuberculous Pleurisy

(2009) Xinchun Chen et al.   JOURNAL OF INFECTIOUS DISEASES

CD28− T cells: their role in the age-associated decline of immune function

(2009) Nan-ping Weng et al.   TRENDS IN IMMUNOLOGY

Characterization of CD8-positive macrophages infiltrating the central nervous system of rats with chronic autoimmune encephalomyelitis

(2008) Keiko Hiraki et al.   JOURNAL OF NEUROSCIENCE RESEARCH